Literature DB >> 31147478

Financial incentives to Medicaid smokers for engaging tobacco quit line treatment: maximising return on investment.

Marlon P Mundt1, Timothy B Baker2,3, Megan E Piper2,3, Stevens S Smith2,3, David L Fraser2, Michael C Fiore2,3.   

Abstract

BACKGROUND: Low-income smokers experience greater difficulty in quitting smoking than do other smokers. Providing financial incentives for treatment engagement increases smoking cessation success. This study models the cost-effectiveness of varying levels of financial incentives to maximise return on investment (ROI) for engaging low-income Medicaid recipients who smoke to take calls from a tobacco quit line.
METHODS: Participants (N=1900) were recruited from May 2013 to June 2015 through quit line-based (n=980), clinic-based (n=444) or community-based referrals (n=476) into the Wisconsin Medicaid Quit Line Incentive project. Incentive (n=948) and control group participants (n=952) received $30 versus $0 per call, respectively, for taking up to five Wisconsin Tobacco Quit Line (WTQL) calls. Cost-effectiveness analyses estimated the incremental cost-effectiveness ratio for alternative financial incentives for engagement with WTQL calls. Probabilistic sensitivity analysis was employed to determine an optimal strategy for financial incentives to minimise the cost per individual who quit smoking.
RESULTS: Using fixed payments, the incremental cost-effectiveness ratio of $2316 per smoker who quit in the randomised trial decreased to $2150 per smoker who quit when the incentives were modelled at $20 per each of five WTQL calls taken. Using variable payments, the minimal cost per additional smoker who quit was $2125 when incentives for the first four WTQL calls were set at $20, and the financial payment for the fifth WTQL call was set at $70.
CONCLUSIONS: Modelling suggests that financial incentives in the amount of $20 per call for taking the first four quit line calls and $70 for taking a fifth quit line call maximise ROI to engage low-income smokers with evidence-based smoking cessation treatment. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cessation; economics; socioeconomic status

Mesh:

Year:  2019        PMID: 31147478      PMCID: PMC8225401          DOI: 10.1136/tobaccocontrol-2018-054811

Source DB:  PubMed          Journal:  Tob Control        ISSN: 0964-4563            Impact factor:   7.552


  29 in total

1.  Struggling to make ends meet: exploring pathways to understand why smokers in financial difficulties are less likely to quit successfully.

Authors:  Amrit Caleyachetty; Sarah Lewis; Ann McNeill; Jo Leonardi-Bee
Journal:  Eur J Public Health       Date:  2012-02       Impact factor: 3.367

Review 2.  Measurement of health state utilities for economic appraisal.

Authors:  G W Torrance
Journal:  J Health Econ       Date:  1986-03       Impact factor: 3.883

3.  A randomized, controlled trial of financial incentives for smoking cessation.

Authors:  Kevin G Volpp; Andrea B Troxel; Mark V Pauly; Henry A Glick; Andrea Puig; David A Asch; Robert Galvin; Jingsan Zhu; Fei Wan; Jill DeGuzman; Elizabeth Corbett; Janet Weiner; Janet Audrain-McGovern
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

4.  What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?

Authors:  R Scott Braithwaite; David O Meltzer; Joseph T King; Douglas Leslie; Mark S Roberts
Journal:  Med Care       Date:  2008-04       Impact factor: 2.983

5.  Tobacco cessation among low-income smokers: motivational enhancement and nicotine patch treatment.

Authors:  Beth C Bock; George D Papandonatos; Marcel A de Dios; David B Abrams; Munawar M Azam; Mark Fagan; Patrick J Sweeney; Michael D Stein; Raymond Niaura
Journal:  Nicotine Tob Res       Date:  2013-10-30       Impact factor: 4.244

6.  A Simulation Modeling Framework to Optimize Programs Using Financial Incentives to Motivate Health Behavior Change.

Authors:  Sanjay Basu; Michaela Kiernan
Journal:  Med Decis Making       Date:  2015-05-14       Impact factor: 2.583

7.  Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6.

Authors:  Andrew H Briggs; Milton C Weinstein; Elisabeth A L Fenwick; Jonathan Karnon; Mark J Sculpher; A David Paltiel
Journal:  Med Decis Making       Date:  2012 Sep-Oct       Impact factor: 2.583

8.  Decision Analysis and Cost-effectiveness Analysis.

Authors:  Hilary F Ryder; Christine McDonough; Anna N A Tosteson; Jon D Lurie
Journal:  Semin Spine Surg       Date:  2009-12

9.  A randomized controlled trial of financial incentives to low income pregnant women to engage in smoking cessation treatment: Effects on post-birth abstinence.

Authors:  Timothy B Baker; David L Fraser; Kate Kobinsky; Robert Adsit; Stevens S Smith; Lisette Khalil; Kristine M Alaniz; Tingting E Sullivan; Mimi L Johnson; Michael C Fiore
Journal:  J Consult Clin Psychol       Date:  2018-02-01

10.  A Randomized Trial of Incentives for Smoking Treatment in Medicaid Members.

Authors:  David L Fraser; Michael C Fiore; Kate Kobinsky; Robert Adsit; Stevens S Smith; Mimi L Johnson; Timothy B Baker
Journal:  Am J Prev Med       Date:  2017-11-02       Impact factor: 5.043

View more
  2 in total

1.  Active referral plus a small financial incentive upon cessation services use on smoking abstinence: a community-based, cluster-randomised controlled trial.

Authors:  Xue Weng; Yongda Wu; Tzu Tsun Luk; William Ho Cheung Li; Derek Yee Tak Cheung; Henry Sau Chai Tong; Vienna Lai; Tai Hing Lam; Man Ping Wang
Journal:  Lancet Reg Health West Pac       Date:  2021-07-05

2.  Smoking Cessation Programs Are Less Effective in Smokers with Low Socioeconomic Status Even When Financial Incentives for Quitting Smoking Are Offered-A Community-Randomized Smoking Cessation Trial in Denmark.

Authors:  Charlotta Pisinger; Cecilie Goltermann Toxværd; Mette Rasmussen
Journal:  Int J Environ Res Public Health       Date:  2022-08-31       Impact factor: 4.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.